Chinese Journal of Pharmacovigilance ›› 2010, Vol. 7 ›› Issue (4): 213-216.

Previous Articles     Next Articles

The Risks and Regulation of Skin Graft Substitute

XU Wei   

  1. Center for Medical Devices Evaluation, SFDA, Beijing 100044, China
  • Received:2016-02-19 Revised:2016-02-19 Online:2010-04-08 Published:2016-02-19

Abstract: Alloskin, heteroskin and tissue engineered skin have been extensively used in clinical. The regulation should be emphasized on the safety and effectiveness since the potential risks of virus transmission and immunological rejection. It analyzed the potential risks associated with the application of Alloskin, heteroskin and tissue engineered skin. The present situation on the regulation of these products also summarized and gives some new suggestions and comments on the regulation enhancement.

Key words: skin graft substitute, risks, regulation

CLC Number: